Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3

Diabetes, Obesity and Metabolism

Volumn 18, Issue 11, 2016, Pages 1081-1088

  Bergenstal, R M ^a   Lunt, H ^b   Franek, E ^c   Travert, F ^d   Mou, J ^e   Qu, Y ^e   Antalis, C J ^e   Hartman, M L ^e   Rosilio, M ^e   Jacober, S J ^e   Bastyr, E J ^e,f  

^a INTERNATIONAL DIABETES CENTER   (United States)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

^c POLISH ACADEMY OF SCIENCES   (Poland)

^d BICHAT HOSPITAL   (France)

^e ELI LILLY AND COMPANY   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

basal insulin; glycaemic control; hypoglycaemia; randomized trial; type 1 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; HEMOGLOBIN A1C; INSULIN ANTIBODY; INSULIN GLARGINE; INSULIN LISPRO; INSULIN PEGLISPRO; TRIACYLGLYCEROL; BASAL INSULIN PEGLISPRO; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; MACROGOL DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BEDTIME DOSAGE; BLOOD PRESSURE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE HYPERTROPHY; INJECTION SITE REACTION; INJECTION SITE SWELLING; INSULIN DEPENDENT DIABETES MELLITUS; LIPOHYPERTROPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOCTURNAL HYPOGLYCEMIA; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; MEAL; METABOLISM; MIDDLE AGED;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN GLARGINE; INSULIN LISPRO; MALE; MEALS; MIDDLE AGED; POLYETHYLENE GLYCOLS;

EID: 84990179399     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12698     Document Type: Article

References (29)

1. Owens DR, Rosenstock J. Current and new long-acting insulin analogs in development: the quest for a better basal insulin. In: Umpierrez GE, ed. Therapy for Diabetes Mellitus and Related Disorders. 6th edn. American Diabetes Association, 2014; 480–507.
2. Knadler MP, Nguyen T-H, Campanale KM et al. Lymphatic absorption of basal insulin peglispro (BIL) in sheep. Diabetes 2015; 64(suppl. 1): A262.
3. Sinha VP, Howey DC, Choi SL, Mace KF, Heise T. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014; 16: 344–350.
4. Sinha VP, Choi SL, Soon DK et al. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. J Clin Pharmacol 2014; 54: 792–799.
5. Henry RR, Mudaliar S, Ciaraldi TP et al. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects. Diabetes Care 2014; 37: 2609–2615.
6. Moore MC, Smith MS, Sinha VP et al. Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes 2014; 63: 494–504.
7. Mudaliar S, Henry RR, Ciaraldi TP et al. Basal insulin peglispro (BIL) demonstrates hepato-preferential action vs. insulin glargine (GL) in patients with type 1 diabetes mellitus (T1DM). Diabetes 2015; 64(suppl 1A): LB22–LB23.
8. Morrow LA, Hompesch M, Jacober SJ et al. Glucodynamics of long-acting basal insulin peglispro (BIL) compared with insulin glargine at steady state in subjects with type 1 diabetes: substudy of a randomized crossover trial. Diabetes Obes Metab 2016; DOI: 10.1111/dom.12691. [Epub ahead of print].
9. Bastyr EJ III, Zhang S, Mou J et al. Performance of an electronic diary system for intensive insulin management in global diabetes clinical trials. Diabetes Technol Ther 2015; 17: 571–579.
10. Center for Drug Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services. Guidance for industry: diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention: 2008 draft. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071624.pdf Accessed June 2016.
11. Dmitrienko A, Tamhane AC, Wiens BL. General multistage gatekeeping procedures. Biom J 2008; 50: 667–677.
12. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: statistical considerations for using multiple endpoints, 2009. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm193282.pdf Accessed June 2016.
13. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245–1249.
14. Luo J, Jacober SJ, Prince MJ, Carey MA, Qu Y. The effect of adjusting for baseline hypoglycemia when analyzing hypoglycemia data: a systematic analysis of 15 diabetes clinical trials. Diabetes Technol Ther 2013; 15: 654–661.
15. Luo J, Qu Y. Analysis of hypoglycemic events using negative binomial models. Pharm Stat 2013; 12: 233–242.
16. Qu Y, Luo J. Estimation of group means when adjusting for covariates in generalized linear models. Pharm Stat 2015; 14: 56–62.
17. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for industry: drug-induced liver injury: premarketing clinical evaluation, 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf Accessed June 2016.
18. Buse JB, Rodbard HW, Trescoli Serrano C et al. Randomized clinical trial comparing basal insulin peglispro and insulin glargine in patients with type 2 diabetes previously treated with basal insulin: imagine 5. Diabetes Care 2016; 39: 92–100.
19. Davies MJ, Russel-Jones D, Selam JL et al. Basal insulin peglispro vs insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial. Diabetes Obes Metab 2016 [Accepted Manuscript].
20. Tang A, Rabasa-Lhoret R, Castel H et al. Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial. Diabetes Care 2015; 38: 1339–1346.
21. Lingvay I, Raskin P, Szczepaniak LS. Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complications 2007; 21: 137–142.
22. Juurinen L, Tiikkainen M, Hakkinen AM, Hakkarainen A, Yki-Jarvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292: E829–835.
23. Ginsberg H, Cariou B, Orchard T et al. Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in 6 IMAGINE trials. Diabetes Obes Metab 2016 [Accepted Manuscript].
24. Schreiber I, Buchfelder M, Droste M et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007; 156: 75–82.
25. Pashankar DS, Loening-Baucke V, Bishop WP. Safety of polyethylene glycol 3350 for the treatment of chronic constipation in children. Arch Pediatr Adolesc Med 2003; 157: 661–664.
26. Au JS, Navarro VJ, Rossi S. Review article: drug-induced liver injury–its pathophysiology and evolving diagnostic tools. Aliment Pharmacol Ther 2011; 34: 11–20.
27. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354: 731–739.
28. Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes 1996; 104: 106–110.
29. Blanco M, Hernandez MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab 2013; 39: 445–453.